Phase I study of the effects of hepatic impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer

MLA

C. Takemoto, et al. “Phase I Study of the Effects of Hepatic Impairment on the Pharmacokinetic (PK) and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer.” Journal of Clinical Oncology, vol. 24, June 2006, p. 2045. EBSCOhost, https://doi.org/10.1200/jco.2006.24.18_suppl.2045.

APA

C. Takemoto, G. Preston, R. F. Setlik, F. E. Nathan, T. Anthony, Michael E. Petrone, C. B. Jones, John Sarantopoulos, T. Dufresne, & D. Greene. (2006). Phase I study of the effects of hepatic impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer. Journal of Clinical Oncology, 24, 2045. https://doi.org/10.1200/jco.2006.24.18_suppl.2045

Chicago

C. Takemoto, G. Preston, R. F. Setlik, F. E. Nathan, T. Anthony, Michael E. Petrone, C. B. Jones, John Sarantopoulos, T. Dufresne, and D. Greene. 2006. “Phase I Study of the Effects of Hepatic Impairment on the Pharmacokinetic (PK) and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer.” Journal of Clinical Oncology 24 (June): 2045. doi:10.1200/jco.2006.24.18_suppl.2045.